deltatrials
Completed PHASE2 INTERVENTIONAL 7-arm NCT03816891

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis

Sponsor: Genentech, Inc.

Conditions Prurigo Nodularis Pruritis
Interventions Placebo Vixarelimab
Updated 34 times since 2019 Last updated: Jan 9, 2026 Started: Mar 11, 2019 Primary completion: Dec 28, 2022 Completion: Aug 24, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Prurigo Nodularis and Pruritis and is currently completed. Genentech, Inc. leads this study, which shows 34 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~May 2020 · 5 months · monthly snapshot~May 2020 – ~Oct 2020 · 5 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Nov 2021 · 5 months · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jun 2022 · 3 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Feb 2023 · 5 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

34 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE2

  3. Jul 2025 — Sep 2025 [monthly]

    Completed PHASE2

  4. Sep 2024 — Jul 2025 [monthly]

    Completed PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE2

▶ Show 29 earlier versions

  1. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE2

  2. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE2

  3. Oct 2023 — Jan 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  7. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE2

  8. Mar 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  9. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  10. Sep 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  11. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  12. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  13. Mar 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  14. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  15. Nov 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  16. Jun 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  17. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  18. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  19. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  20. May 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  21. Dec 2019 — May 2020 [monthly]

    Recruiting PHASE2

  22. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  23. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  24. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  25. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  26. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  27. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  28. Mar 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE2

  29. Feb 2019 — Mar 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Bentheim, Germany , Barrie, Canada , Beverly, United States , Bielefeld, Germany , Bordeaux, France , Brescia, Italy , Brest, France , Brussels, Belgium , Catania, Italy , Centennial, United States and 67 more locations